Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
CONTACT
PARTICIPANT AREA
Login
▹
Publications
▹
Home
Publication
The role of a murine transplantation model of atherosclerosis regression in drug
discovery.
Authors
Feig JE, Quick JS, Fisher EA
Submitted By
Edward Fisher on 8/30/2012
Status
Published
Journal
Current opinion in investigational drugs (London, England : 2000)
Year
2009
Date Published
3/1/2009
Volume : Pages
10 : 232 - 238
PubMed Reference
19333880
Abstract
Atherosclerosis is the leading cause of death worldwide. To date, the use of
statins to lower LDL levels has been the major intervention used to delay or
halt disease progression. These drugs have an incomplete impact on plaque burden
and risk, however, as evidenced by the substantial rates of myocardial
infarctions that occur in large-scale clinical trials of statins. Thus, it is
hoped that by understanding the factors that lead to plaque regression, better
approaches to treating atherosclerosis may be developed. A transplantation-based
mouse model of atherosclerosis regression has been developed by allowing plaques
to form in a model of human atherosclerosis, the apoE-deficient mouse, and then
placing these plaques into recipient mice with a normolipidemic plasma
environment. Under these conditions, the depletion of foam cells occurs.
Interestingly, the disappearance of foam cells was primarily due to migration in
a CCR7-dependent manner to regional and systemic lymph nodes after 3 days in the
normolipidemic (regression) environment. Further studies using this transplant
model demonstrated that liver X receptor and HDL are other factors likely to be
involved in plaque regression. In conclusion, through the use of this transplant
model, the process of uncovering the pathways regulating atherosclerosis
regression has begun, which will ultimately lead to the identification of new
therapeutic targets.
Investigators with authorship
Name
Institution
Edward Fisher
New York University School of Medicine
Complications
All Complications
Bioinformatics
Bone
Cardiomyopathy
Cardiovascular
Gastro-Intestinal (GI)
Nephropathy
Neuropathy & Neurocognition
Pediatric Endocrinology
Retinopathy
Uropathy
Wound Healing
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!